title: Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation.
abstract: Background. Disability in multiple sclerosis (MS) is related to neuroaxonal degeneration. A reliable blood biomarker for neuroaxonal degeneration is needed. Objectives. To explore the relationship between cerebrospinal fluid (CSF) and serum concentrations of a protein biomarker for neuroaxonal degeneration, the neurofilaments heavy chain (NfH). Methods. An exploratory cross-sectional (n = 51) and longitudinal (n = 34) study on cerebrospinal fluid (CSF) and serum NfH phosphoform levels in patients with MS. The expanded disability status scale (EDSS), CSF, and serum levels of NfH-SMI34 and NfH-SMI35 were quantified at baseline. Disability progression was assessed at 3-year followup. Results. At baseline, patients with primary progressive MS (PPMS, EDSS 6) and secondary progressive MS (SPMS, EDSS 6) were more disabled compared to patients with relapsing remitting MS (RRMS, EDSS 2, P < .0001). Serum and CSF NfH phosphoform levels were not correlated. Baseline serum levels of the NfH-SMI34 were significantly (P < .05) higher in patients with PPMS (2.05 ng/mL) compared to SPMS (0.03 ng/mL) and RRMS (1.56 ng/mL). In SPMS higher serum than CSF NfH-SMI34 levels predicted disability progression from baseline (ΔEDSS 2, P < .05). In RRMS higher CSF than serum NfH-SMI35 levels predicted disability progression (ΔEDSS 2, P < .05). Conclusion. Serum and CSF NfH-SMI34 and NfH-SMI35 levels did not correlate with each other in MS. The quantitative relationship of CSF and serum NfH levels suggests that neuroaxonal degeneration of the central nervous system is the likely cause for disability progression in RRMS. In more severely disabled patients with PP/SPMS, subtle pathology of the peripheral nervous system cannot be excluded as an alternative source for blood NfH levels. Therefore, the interpretation of blood protein biomarker data in diseases of the central nervous system (CNS) should consider the possibility that pathology of the peripheral nervous system (PNS) may influence the results.
authors.affiliation: Department of Neurology, MS Center Amsterdam, VU University Medical Center, Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: Eikelenboom
authors.forename: B M J
authors.initials: BM
authors.lastname: Uitdehaag
authors.forename: A
authors.initials: A
authors.lastname: Petzold
references.citation: J Neurotrauma. 2009 Nov;26(11):1867-77
references.pmid: 19811094
references.citation: J Neurol Sci. 1994 Apr;122(2):189-203
references.pmid: 8021703
references.citation: Neurology. 1996 Apr;46(4):907-11
references.pmid: 8780061
references.citation: Neurology. 2009 Apr 14;72(15):1322-9
references.pmid: 19365053
references.citation: Eur J Neurol. 2011 May;18(5):789-91
references.pmid: 20629712
references.citation: Neurology. 2004 Nov 9;63(9):1586-90
references.pmid: 15534240
references.citation: Ann Neurol. 1977 Jul;2(1):41-8
references.pmid: 900906
references.citation: Mult Scler. 2008 Jan;14(1):59-66
references.pmid: 17893112
references.citation: Suppl Clin Neurophysiol. 2004;57:85-90
references.pmid: 16106609
references.citation: Ann Neurol. 2006 Mar;59(3):478-89
references.pmid: 16392116
references.citation: Mult Scler. 2010 Mar;16(3):287-92
references.pmid: 20086018
references.citation: Clin Neurophysiol. 2007 Aug;118(8):1753-8
references.pmid: 17573238
references.citation: Brain. 1997 Jun;120 ( Pt 6):1085-96
references.pmid: 9217691
references.citation: Brain. 1997 Mar;120 ( Pt 3):393-9
references.pmid: 9126051
references.citation: J Immunol Methods. 2003 Jul;278(1-2):179-90
references.pmid: 12957406
references.citation: Neurology. 2009 Dec 1;73(22):1914-22
references.pmid: 19949037
references.citation: J Neurol Neurosurg Psychiatry. 2005 Feb;76(2):206-11
references.pmid: 15654034
references.citation: Lancet Neurol. 2005 Jan;4(1):32-41
references.pmid: 15620855
references.citation: Neurol Res. 2007 Oct;29(7):691-708
references.pmid: 18173909
references.citation: Restor Neurol Neurosci. 2003;21(3-4):79-96
references.pmid: 14530572
references.citation: Brain. 2002 Jul;125(Pt 7):1462-73
references.pmid: 12076997
references.citation: N Engl J Med. 1998 Jan 29;338(5):278-85
references.pmid: 9445407
references.citation: Neurology. 2003 Jan 28;60(2):219-23
references.pmid: 12552034
references.citation: J Neurotrauma. 2008 Sep;25(9):1079-85
references.pmid: 18729720
references.citation: J Neuroimmunol. 2010 Mar 30;220(1-2):114-9
references.pmid: 20117845
references.citation: J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1178-80
references.pmid: 15258226
references.citation: Neurology. 1983 Nov;33(11):1444-52
references.pmid: 6685237
references.citation: Muscle Nerve. 1982 May-Jun;5(5):411-4
references.pmid: 6289099
references.citation: Arch Neurol. 2009 May;66(5):601-9
references.pmid: 19433660
references.citation: Exp Neurol. 2008 Oct;213(2):326-35
references.pmid: 18619438
references.citation: Brain. 2011 Feb;134(Pt 2):464-83
references.pmid: 21278408
references.citation: Neurocrit Care. 2010 Jun;12(3):324-36
references.pmid: 20225002
references.citation: Brain Pathol. 2011 Jul;21(4):428-40
references.pmid: 21114565
references.citation: J Cell Biol. 1996 Nov;135(3):711-24
references.pmid: 8909545
references.citation: Biochem Biophys Res Commun. 2005 Nov 4;336(4):1268-77
references.pmid: 16176808
references.citation: Neurochem Res. 2011 Mar;36(3):528-32
references.pmid: 21191652
references.citation: Muscle Nerve. 1995 Oct;18(10):1216-7
references.pmid: 7659122
references.citation: Clin Neurophysiol. 2001 Sep;112(9):1575-85
references.pmid: 11514239
references.citation: J Neurol Sci. 2005 Jun 15;233(1-2):183-98
references.pmid: 15896809
references.citation: Mult Scler. 2004 Jun;10(3):281-3
references.pmid: 15222692
references.citation: Lancet Neurol. 2009 Mar;8(3):280-91
references.pmid: 19233038